Not Yet RecruitingNot Applicable

Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization

156 participantsStarted 2026-10-01

Plain-language summary

The study investigates the role of Lipoprotein(a) \[Lp(a)\] levels in predicting cardiovascular risk and adverse events in patients undergoing elective percutaneous coronary intervention (PCI).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 years or older Undergoing elective PCI for stable coronary artery disease Ability to provide informed consent Willingness to undergo blood sampling prior to PCI Exclusion Criteria: * Acute coronary syndrome within 30 days Cardiogenic shock Prior heart transplant or left ventricular assist device (LVAD) Life expectancy less than 1 year due to non-cardiac causes Participation in a blinded Lp(a)-lowering outcome trial at the time of enrollment

What they're measuring

Incidence of major adverse cardiovascular events (MACE)

Timeframe: one year

Trial details

NCT IDNCT07197242

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-06-30

View on ClinicalTrials.gov More PCI trials